vs

Side-by-side financial comparison of Sunrise New Energy Co., Ltd. (EPOW) and STANDARD BIOTOOLS INC. (LAB). Click either name above to swap in a different company.

Sunrise New Energy Co., Ltd. is the larger business by last-quarter revenue ($22.3M vs $19.6M, roughly 1.1× STANDARD BIOTOOLS INC.). Sunrise New Energy Co., Ltd. runs the higher net margin — -27.1% vs -177.4%, a 150.3% gap on every dollar of revenue. On growth, Sunrise New Energy Co., Ltd. posted the faster year-over-year revenue change (0.0% vs -11.5%).

Husky Energy Inc. was a Canadian petroleum company that existed from 1938 to 2021. It operated in Western and Atlantic Canada, the United States and the Asia Pacific region, with upstream and downstream business segments. In the 2020 Forbes Global 2000, Husky Energy was ranked as the 1443rd-largest public company in the world.

Standard BioTools Inc., previously known as Fluidigm Corp., is an American life science tools company that offers analytical mass cytometry systems for flow cytometry and tissue imaging, along with associated assays and reagents, as well as an automated genomic analysis instrument and a variety of microfluidic arrays, or integrated fluidic circuits (IFCs), and consumables with fully kitted reagents. Custom assays and services are available with all systems and applications.

EPOW vs LAB — Head-to-Head

Bigger by revenue
EPOW
EPOW
1.1× larger
EPOW
$22.3M
$19.6M
LAB
Growing faster (revenue YoY)
EPOW
EPOW
+11.5% gap
EPOW
0.0%
-11.5%
LAB
Higher net margin
EPOW
EPOW
150.3% more per $
EPOW
-27.1%
-177.4%
LAB

Income Statement — Q2 FY2025 vs Q3 FY2025

Metric
EPOW
EPOW
LAB
LAB
Revenue
$22.3M
$19.6M
Net Profit
$-6.0M
$-34.7M
Gross Margin
0.1%
48.5%
Operating Margin
-24.3%
-168.5%
Net Margin
-27.1%
-177.4%
Revenue YoY
0.0%
-11.5%
Net Profit YoY
-35.7%
-28.8%
EPS (diluted)
$-0.09

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
EPOW
EPOW
LAB
LAB
Q3 25
$19.6M
Q2 25
$22.3M
$21.8M
Q1 25
$40.8M
Q3 24
$22.1M
Q2 24
$22.3M
$22.5M
Q1 24
$45.5M
Q4 23
$28.2M
Q3 23
$25.4M
Net Profit
EPOW
EPOW
LAB
LAB
Q3 25
$-34.7M
Q2 25
$-6.0M
$-33.5M
Q1 25
$-26.0M
Q3 24
$-26.9M
Q2 24
$-4.5M
$-45.7M
Q1 24
$-32.2M
Q4 23
$-19.8M
Q3 23
$-21.0M
Gross Margin
EPOW
EPOW
LAB
LAB
Q3 25
48.5%
Q2 25
0.1%
48.8%
Q1 25
48.4%
Q3 24
54.9%
Q2 24
0.1%
46.1%
Q1 24
53.1%
Q4 23
47.6%
Q3 23
44.0%
Operating Margin
EPOW
EPOW
LAB
LAB
Q3 25
-168.5%
Q2 25
-24.3%
-118.1%
Q1 25
-80.8%
Q3 24
-120.9%
Q2 24
-24.3%
-134.5%
Q1 24
-132.2%
Q4 23
-75.9%
Q3 23
-83.5%
Net Margin
EPOW
EPOW
LAB
LAB
Q3 25
-177.4%
Q2 25
-27.1%
-153.7%
Q1 25
-63.8%
Q3 24
-122.0%
Q2 24
-20.0%
-203.3%
Q1 24
-70.6%
Q4 23
-70.2%
Q3 23
-82.8%
EPS (diluted)
EPOW
EPOW
LAB
LAB
Q3 25
$-0.09
Q2 25
$-0.09
Q1 25
$-0.07
Q3 24
$-0.07
Q2 24
$-0.21
$-0.12
Q1 24
$-0.27
Q4 23
$-0.24
Q3 23
$-0.27

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
EPOW
EPOW
LAB
LAB
Cash + ST InvestmentsLiquidity on hand
$1.3M
$129.4M
Total DebtLower is stronger
Stockholders' EquityBook value
$27.3M
$399.7M
Total Assets
$143.0M
$539.6M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
EPOW
EPOW
LAB
LAB
Q3 25
$129.4M
Q2 25
$1.3M
$158.6M
Q1 25
$150.9M
Q3 24
$210.6M
Q2 24
$15.2M
$269.8M
Q1 24
$287.1M
Q4 23
$51.7M
Q3 23
$79.7M
Total Debt
EPOW
EPOW
LAB
LAB
Q3 25
Q2 25
Q1 25
Q3 24
$55.2M
Q2 24
$55.1M
Q1 24
$55.0M
Q4 23
$63.5M
Q3 23
$64.6M
Stockholders' Equity
EPOW
EPOW
LAB
LAB
Q3 25
$399.7M
Q2 25
$27.3M
$424.5M
Q1 25
$454.6M
Q3 24
$489.3M
Q2 24
$-2.8M
$510.3M
Q1 24
$577.3M
Q4 23
$-148.1M
Q3 23
$-131.7M
Total Assets
EPOW
EPOW
LAB
LAB
Q3 25
$539.6M
Q2 25
$143.0M
$557.0M
Q1 25
$579.6M
Q3 24
$681.5M
Q2 24
$141.6M
$708.7M
Q1 24
$777.7M
Q4 23
$323.1M
Q3 23
$339.3M
Debt / Equity
EPOW
EPOW
LAB
LAB
Q3 25
Q2 25
Q1 25
Q3 24
0.11×
Q2 24
0.11×
Q1 24
0.10×
Q4 23
Q3 23

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
EPOW
EPOW
LAB
LAB
Operating Cash FlowLast quarter
$-6.9M
$-22.2M
Free Cash FlowOCF − Capex
$-23.1M
FCF MarginFCF / Revenue
-118.1%
Capex IntensityCapex / Revenue
4.5%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-111.1M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
EPOW
EPOW
LAB
LAB
Q3 25
$-22.2M
Q2 25
$-6.9M
$-20.7M
Q1 25
$-30.3M
Q3 24
$-27.9M
Q2 24
$-6.9M
$-39.0M
Q1 24
$-62.5M
Q4 23
$-14.1M
Q3 23
$-11.4M
Free Cash Flow
EPOW
EPOW
LAB
LAB
Q3 25
$-23.1M
Q2 25
$-22.6M
Q1 25
$-35.3M
Q3 24
$-30.1M
Q2 24
$-7.9M
$-41.0M
Q1 24
$-63.3M
Q4 23
$-14.1M
Q3 23
$-12.3M
FCF Margin
EPOW
EPOW
LAB
LAB
Q3 25
-118.1%
Q2 25
-103.6%
Q1 25
-86.6%
Q3 24
-136.4%
Q2 24
-35.6%
-182.2%
Q1 24
-138.9%
Q4 23
-50.2%
Q3 23
-48.6%
Capex Intensity
EPOW
EPOW
LAB
LAB
Q3 25
4.5%
Q2 25
8.7%
Q1 25
12.4%
Q3 24
10.2%
Q2 24
4.4%
8.6%
Q1 24
1.7%
Q4 23
0.3%
Q3 23
3.6%

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

EPOW
EPOW

Segment breakdown not available.

LAB
LAB

Consumables$8.7M45%
Services And Other Revenue$5.8M29%
Instruments$5.1M26%

Related Comparisons